Table 1.
Participant demographics
| Age, yr | Sex | Height, m | Mass, kg | PD Duration, yr | UPDRS-III | H&Y | CBF | PD Phenotype | Medications | |
|---|---|---|---|---|---|---|---|---|---|---|
| PR1 | 68 | M | 1.8 | 80.6 | 5 | 26 | 2 | 24 | PIGD (0.14/1.00) | C/L, Ent, Rop |
| PR2 | 79 | M | 1.68 | 68.0 | 3 | 40 | 2 | 19 | PIGD (0.57/1.00) | C/L, Ama |
| PR3 | 64 | M | 1.75 | 79.3 | 11 | 25 | 2.5 | 20 | PIGD (0.00/0.50) | C/L, Ent |
| PR7 | 36 | M | 1.83 | 74.7 | 6 | 29 | 2 | 24 | TD (1.71/0.00) | C/L |
| PR8 | 81 | F | 1.65 | 48.9 | 14 | 31 | 3 | 22 | PIGD (0.00/0/50 | C/L, Rop |
| PR9 | 56 | M | 1.85 | 82.9 | 3 | 28 | 2 | 22 | Indet (0.71/0.50) | C/L |
PD, Parkinson’s disease; UPDRS-III, Unified Parkinson’s Disease Rating Motor Subscale III; H&Y, Hoehn and Yahr scale; PIGD, postural instability/gait disability dominant; TD, tremor dominant; Indet, indeterminate C/L, carbidopa/levodopa; Ent, entacapone; Rop, ropinerole; Ama, amantadine. Physical function reported with composite physical function (Rikli and Jones 1999). PD phenotype presented as the ratio of average scores on UPDRS-III for posture and gait items/tremor items. Participant codes are as in McKay et al. (2016).